Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | SVP, Chief Medical Officer | March 16, 2020 | March 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date March 16, 2020 · Filed March 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2030-03-16 | Direct | 50,000 |
Reported balance
After 2020-03-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-16 · Grant · Acquired 50,000 · Balance 50,000 F1: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. |
Filing footnotes · ownership attribution and instrument terms
F1: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2020 Filed Mar 18, 2020 20:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001214659-20-002754 · marketforms-48341.xml · derivative · entry 1 Slatko Gary H · CIK 0001763416 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| January 02, 2019 Filed Jan 7, 2019 16:28 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 75,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0001214659-19-000170 · marketforms-43687.xml · derivative · entry 1 Slatko Gary H · CIK 0001763416 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying the options vest in three annual installments of 25%, 25% and 50% on January 2, 2020, January 2, 2021 and January 2, 2022, respectively, subject in each case to Dr. Slatko's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.